This retrospective real-life study aims to determine if Finnish patients receiving biological therapy for severe asthma benefit from the treatment due to reduction in exacerbations, OCS dose and courses of OCS and antibiotics in a real-life setting with a broader population than in a randomised controlled trial, and to compare anti-IL5/IL5R therapy results with anti-IgE therapy results in a real-life setting. It also aims to describe the impact of biological therapy on upper respiratory tract findings and need for treatment in asthma patients receiving biologicals.
Featured article: A comparison of biologicals in the treatment of adults with severe asthma – real-life experiences
Articles
-
-
A comparison of biologicals in the treatment of adults with severe asthma – real-life experiences
-
Determinants of Acute Asthma Attack among adult asthmatic patients visiting hospitals of Tigray, Ethiopia, 2019: case control study
-
Determinants of non-adherence to inhaled steroids in adult asthmatic patients on follow up in referral hospital, Ethiopia: cross-sectional study
-
Development of a framework for increasing asthma awareness in Chitungwiza, Zimbabwe
COVID-19 and impact on peer review
As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Aims and scope
Asthma Research and Practice publishes cutting edge basic, clinical and translational research in addition to hot topic reviews and debate articles relevant to asthma and related disorders (such as rhinitis, COPD overlapping syndrome, sinusitis). The journal has a specialized section which focusses on pediatric asthma research.
Asthma Research and Practice aims to serve as an international platform for the dissemination of research of interest to pulmonologists, allergologists, primary care physicians and family doctors, ENTs and other health care providers interested in asthma, its mechanisms and comorbidities.
Advertisement
Follow
Annual Journal Metrics
-
Speed
80 days to first decision for reviewed manuscripts only
78 days to first decision for all manuscripts
133 days from submission to acceptance
16 days from acceptance to publicationCitation Impact
2.917 - Source Normalized Impact per Paper (SNIP)
1.274 - SCImago Journal Rank (SJR)
4.460 - CiteScoreUsage
74,526 Downloads
59 Altmetric mentions
Advertisement
